🧪 Maduramycin is especially beneficial for subcutaneously-administered biologics and offers an alternative to existing modulators.
👩🔬 Scientists found that maduramycin increased M5 glycans for mAbs in both fed-batch and steady-state perfusion processes.
🔬 The combination of maduramycin and kifunensine allows manufacturers to control high-mannose distribution in manufacturing processes.
Introduction:
A recent study published in GEN explores the use of the M5 modulator, maduramycin, in tailoring monoclonal antibody (mAb) glycosylation. M5 modulators are important in bioprocessing as they affect cytotoxicity and half-life of mAbs. Maduramycin has shown promise in increasing M5 glycans for mAbs and offers an alternative to currently used modulators such as monensin and kifunensine. Furthermore, maduramycin may be particularly beneficial for subcutaneously-administered biologics.
- M5 modulators play a crucial role in the production and reformulation of mAbs, affecting cytotoxicity and half-life.
- Maduramycin, a recently discovered modulator, is efficient in increasing M5 glycans for mAbs.
- Maduramycin may be particularly beneficial for subcutaneously-administered biologics due to the absence of serum α-mannosidase.
- Research suggests that a combination of maduramycin and kifunensine enables manufacturers to control high-mannose distribution for continuous and fed-batch mAb manufacturing.
- Further studies are needed to fully understand the mechanism of action of maduramycin.
Conclusion:
The use of the M5 modulator, maduramycin, shows promise in tailoring monoclonal antibody glycosylation. It offers an alternative to currently used modulators and may be particularly beneficial for subcutaneously-administered biologics. However, more research is needed to fully understand the mechanism of action of maduramycin and its potential implications for biomanufacturing processes.
